research Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens
Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Comparison of the effects of the K+-channel openers cromakalim and minoxidil sulphate on vascular smooth muscle
Cromakalim relaxes various blood vessels, while minoxidil sulphate is more selective; they likely act on different potassium channels.
research Oral cyclosporin does not arrest progression of androgenetic alopecia.
Oral cyclosporin doesn't stop hair loss.
research An Experimental Study of Morphofunctional Features of Hair Follicles Early Response in Cyclophosphamide-Induced Alopecia
Miliacin helps damaged hair follicles grow new hair faster.
research Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.
research Efficacy and Safety of a Proprietary Free Fatty Acid Rich Saw Palmetto Extract (USPlus® PRO) for Lower Urinary Tract Symptoms in Males: A Randomized, Double-Blind, Placebo-Controlled Trial
USPlus PRO saw palmetto extract improves urinary symptoms and is safe for men.
research Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
Dutasteride effectively treats enlarged prostate with manageable side effects.
research A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
Entadfi, a mix of finasteride and tadalafil, is used for BPH.
research Topical cyclosporine in male pattern alopecia
Topical cyclosporine led to significant hair growth in some men with male pattern baldness.
research Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
research Clascoterone: a new topical antiandrogen agent.
Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
![Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)](/images/assets/d743d32f-3115-48ff-9697-2f2d56130701/small/14175.jpg)
research Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)
The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
research Evaluation of New Pregnane Derivatives as 5.ALPHA.-Reductase Inhibitor.
New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research Screen steroid 5 alpha-reductase inhibitors in vitro by high performance liquid chromatography
The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
research Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*
Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.
research 732 Treatment with cyclohexyl salicylate, an olfactory receptor 2A4/7 agonist, promotes human hair follicle growth and bulge stem cell progeny expansion
Cyclohexyl salicylate promotes human hair growth and increases certain hair follicle stem cell progeny.
research 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Effect of Cuscuta reflexa Extract in Mitigating Testosterone-Induced Benign Prostatic Hyperplasia in Rats: Targeting Inflammation and Oxidative Stress
Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
research Finasterid in der Behandlung der benignen Prostatahyperplasie
Finasteride effectively reduces prostate size and symptoms in most BPH patients.
research La clinoïdectomie antérieure extra-durale dans l'abord des méningiomes sus-tentoriels de la base du crâne. À propos d'une série de 142 cas
Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
research 3a-Phenylhexahydropentalene-1,6-dione
A rigid compound with a common structural motif was successfully synthesized.
research Prednisolone
A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.
research Konvergentna validacija farmakoekonomskih aspekata terapije benigne hiperplazije prostate u Crnoj Gori
Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
research Preparation of novel polymeric microspheres for controlled release of finasteride
PPCM microspheres allow controlled finasteride release over 24 hours.
research Discontinuation of Alpha-Blockade after Initial Treatment with Finasteride and Doxazosin for Bladder Outlet Obstruction
Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
research Preparation of finasteride by selective dehydrogenation using IBX
The method produces finasteride with a 92% yield.
research Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model
Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.